Skip to main content
HR 7701 116th Congress House Health Alternative treatments Business ethics Business records Congressional oversight Drug safety, medical device, and laboratory regulation Drug therapy Drug trafficking and controlled substances Drug, alcohol, tobacco use Emergency medical services and trauma care Government information and archives Government studies and investigations Health care costs and insurance Health care coverage and access Health care quality Health information and medical records Health personnel Health programs administration and funding Health promotion and preventive care Health technology, devices, supplies

Addiction Prevention and Responsible Opioid Practices Act

Introduced: July 21, 2020 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 21, 2020
Referred to the Subcommittee on Health.
Jul 21, 2020
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Education and Labor, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jul 21, 2020
Introduced in House
 Plain-English summary Congressional Research Service

Addiction Prevention and Responsible Opioid Practices Act

This bill addresses substance use and mental health related to opiods, including by imposing an excise tax on opioids; modifying controlled substances regulations, prescription drug monitoring programs (PDMPs), and health insurance coverage; and requiring other activities.

Specifically, the bill (1) establishes federal licensure requirements for pharmaceutical representatives who market opioids, (2) requires certain training and PDMP participation as conditions for controlled substance registration, and (3) withdraws regulatory approval for opioids with ultra-high doses.

In addition, as a condition for receiving certain grants, recipients must, for example, mandate the use of PDMPs in specified ways and increase data-sharing. Additionally, to meet certain certification standards, health information technology must be interoperable with PDMPs.

Additionally, the Centers for Medicare & Medicaid Services (CMS) must reimburse mental health services provided through telehealth under Medicare and develop a web-based tool to compare opioid prescribing in state Medicaid programs. The bill also creates grants to support compliance with requirements to provide parity in insurance coverage for mental health and substance use disorder services. The Government Accountability Office must study health care coverage and reimbursements for substance use disorder treatments.

Furthermore, the Department of Health and Human Services and the CMS must develop quality measures and guidelines for treatment of non-fatal overdoses, and the Department of Justice must operate a drug take-back program. The National Academies of Sciences, Engineering, and Medicine and medical and dental schools must also report on Medicare coverage of non-opioid treatment for back pain and educational courses on pain management and opioid prescribing practices, respectively.

What's happening now July 21, 2020

Referred to the Subcommittee on Health.

 Committees of jurisdiction 5
 Cosponsors 1
All 1 Democratic 1